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cultures, spheroids better predict effi cacy 
of therapeutics, which can reduce use 
of animals in drug testing by identifying 
ineffective compounds in vitro. [ 4 ] None-
theless, cancer cell spheroids are not 
commonly employed for drug screening 
because of limitations of current methods 
for generating, maintaining, treating, and 
analyzing drug responses in 3D formats. 
The traditional liquid overlay method for 
producing spheroids blocks cell adhesion 
to an underlying surface and retains cells 
suspended, resulting in random-sized 
spheroids. [ 5 ] Rotary vessel and spinner 
fl ask technologies continuously spin cells 
and maintain them in suspension to mass 
produce spheroids; [ 6,7 ] however applied 
shear forces, non-uniform size and har-
vesting of resulting spheroids remain 
key limitations. Traditional and new tech-
niques based on hanging drops utilize 
gravity to induce formation of spheroids 
of controlled size at the apex of drops. [ 8,9 ] 
Hanging drop methods inherently face 
several challenges: addition of media 
and reagents, media evaporation, loss or 
merger of spheroids during handling, and transfer of sphe-
roids into a standard microplate for downstream analyses. Plat-
forms based on microfabrication allow culturing of uniform 
size spheroids, but the depth of micro-channels/wells/spheres 
(often 100–200 µm) limits the size of spheroids and impedes 
downstream analyses. [ 10 ] As such, existing techniques are very 
diffi cult to implement for mass producing spheroids of uni-
form, pre-defi ned size that are easy to maintain, individually 
treat with biological reagents, and biochemically analyze. 
 We report a novel microtechnology that enables high 
throughput 3D culture and analysis of cancer cells as con-
sistent-size cellular spheroids. Our approach is based on the 
use of a polymeric aqueous two-phase system (ATPS) to confi ne 
cells within a nanoliter-volume aqueous drop immersed within 
a second, immersion aqueous phase. Cells remain in close 
proximity and aggregate to spontaneously form a spheroid. 
The resulting spheroids mimic key features of solid tumors 
including hypoxia and restricted diffusion of nutrients and 
drugs, while preserving reproducibility of standard two-dimen-
sional cultures. This microtechnology eliminates shortcomings 
of existing techniques by offering full compatibility with robotic 
tools and screening instruments to allow straightforward cul-
ture, maintenance, drug treatment, and biochemical analysis of 
cellular spheroids all within a standard microwell plate. 
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 1.  Introduction 
 Three-dimensional (3D) cultures of cancer cells as spheroids 
provide an important tool for tissue engineering and drug 
testing due to their physiological relevance compared to widely 
used monolayer cultures. [ 1–3 ] As compared with monolayer 
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 2.  Results and Discussion 
 2.1.  Aqueous Two-Phase System Phase Diagram 
 We selected a polymeric ATPS comprising of dextran (DEX, 
Mw: 500 k) and polyethylene glycol (PEG, Mw: 35 k) as the 
phase forming polymers due to their biocompatibility and the 
possibility of forming ATPS at low polymer concentrations. [ 11,12 ] 
To determine the range of working concentrations, we gener-
ated an experimental phase diagram that prescribes required 
pairs of concentrations from the two polymers to result in an 
ATPS. [ 13 ] A binodal curve was formed representing critical ini-
tial phase concentrations of polymers above which a biphasic 
system forms, whereas any pair of concentrations below the 
binodal curve results in a single aqueous phase ( Figure  1 ). We 
selected a biphasic system consisting of phase concentrations 
of 5%(w/w) PEG and 6.4%(w/w) DEX, in their respective stock 
solutions, for the spheroid assay due to its low polymer con-
tent and providing a mild and highly aqueous environment 
for cells. With the selected concentrations, the intersection of 
the binodal curve with the tie line shows the composition of 
fi nal equilibrated phases (Figure  1 ). Due to a small density dif-
ference of 0.018 g/cm 3 , the denser DEX-rich aqueous solution 
forms the bottom phase and the lighter PEG-rich aqueous solu-
tion makes up the top phase. We note that our previous studies 
have shown that PEG-DEX ATPS is fully compatible with cells 
and supports highly viable and functional cells. [ 11,14 ] 
 2.2.  Spheroid Generation with PEG-DEX Aqueous Two-Phase 
System 
 We used the PEG phase solution as the immersion medium 
and the aqueous DEX phase as the patterning phase. Dis-
pensing a nanoliter-volume drop of the aqueous DEX phase 
into a reservoir containing the aqueous PEG phase resulted 
in a completely stable round drop that settled and remained 
immiscible from the immersion phase ( Figure  2 a). To generate 
a spheroid, fi rst a well of a standard 96-well plate was loaded 
with 50 µL of the aqueous PEG phase. Then equal volumes of 
the aqueous DEX phase prepared twice concentrated, that is, 
12.8%(w/w), and the cell suspension of a desired density were 
mixed. The resulting solution containing cells had a 6.4%(w/w) 
polymer concentration. Next, 300 nl of the resulting mixture 
was pipetted into the immersion PEG phase to form a cell-
containing drop at the well bottom. During incubation, cells 
remained confi ned within the drop and spontaneously formed a 
spheroid within 24 hrs, without any external forces and stimuli 
(Figure  2 b). The spheroid presents a normal morphology 
with a darker core, brighter periphery, and a clear boundary. [ 3 ] 
Over 7 days of incubation, spheroids form a compact cellular 
mass (Figure  2 c). This approach accommodates spheroids 
with a wide range of cell densities, as few as 1 × 10 3 cells and 
as many as 1 × 10 5 cells per drop, to produce spheroids with 
approximate diameters of 125 µm and 900 µm, respectively. 
Importantly, our quantitative analysis resulted in an empirical 
relation that allows pre-defi ning the size of spheroids from a 
cell density within the range of 1 × 10 3 –1 × 10 5 cells per drop 
(Figure  2 d). We further confi rmed the utility of this approach 
for spheroid formation by two different cancer cell lines, A431.
H9 skin cancer cells and MDA-MB-157 breast cancer cells. 
 2.3.  Versatility of Aqueous Two-phase Systems for Spheroid 
Culture 
 Next we demonstrated the versatility of ATPS-mediated sphe-
roid culture by evaluating the feasibility of generating sphe-
roids with different combinations of aqueous solutions of a 
panel of six polymers ( Figure  3 ). The criteria for selecting these 
polymers were compatibility with cell culture, and forming 
an ATPS as reported previously. [ 15 ] Aqueous solutions of each 
polymer were prepared at concentrations of 
5%, 10%, 15%, and 20%(w/w). Solutions of 
each two polymers were mixed to determine 
the capability of ATPS formation within this 
concentration range. This resulted in 16 
combinations for each pair of polymers (Sup-
porting Information, Figure SI-1). This com-
prehensive analysis led to pairs of polymeric 
aqueous solutions that formed an ATPS, with 
at least one combination of concentrations 
(hatched cells in the upper right diagonal of 
Figure  3 ). 
 Next these systems were tested for their 
ability to form a spheroid. From each pair 
of polymers, we selected only one ATPS 
containing the smallest concentrations of 
polymers to ensure each phase remains 
highly aqueous with minimal changes in 
the composition of culture medium (Figure 
SI-1). From the panel of polymers studied 
(Figure  3 and Figure SI-1), PEG35k-DEX500k 
pair required only a total of 10%(w/w) of 
polymers to form an ATPS and generate 
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 Figure 1.  Experimental phase diagram of an ATPS with PEG35k and DEX500k as phase-forming 
polymers. The diagram shows a binodal curve above which combinations of concentrations of 
two polymers give rise to a two-phase system (top inset image). Below the binodal curve, phase 
separation does not happen (bottom inset image). With an initial concentration of 6.4%(w/w) 
DEX and 5%(w/w) PEG (open circle), a two-phase system with specifi c compositions of top and 
bottom phases forms (hatched circles). The intersection of the tie line and the binodal curve 
shows the concentration of top PEG-rich phase and bottom DEX-rich phase. The dashed tie line 
is only a schematic. Precise quantities of equilibrated phases are 3.16%(w/w) PEG-1.57%(w/w) 
DEX in the PEG-rich phase and 0.72%(w/w) PEG-7.14%(w/w) DEX in the PEG-rich phase. 
The binodal curve equation is [PEG]=0.0436 exp{-4.38[DEX] 0.5 -1712.3[DEX] 3 }, where [PEG] and 
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spheroids, that is, a minimum of 5%(w/w) from each polymer. 
The minimum concentration of polymers to give a two-phase 
system increased with other polymer pairs to 15–35%(w/w) of 
total polymer fraction in ATPS. Out of the eight polymer pairs 
whose aqueous solutions showed phase separation, six ATPS 
with a total polymer content of up to 25%(w/w) resulted in suc-
cessful formation of spheroids (hatched cells in the lower left 
diagonal of Figure  3 ). These results suggest that high polymer 
concentrations can impede spheroid formation in ATPS and 
thus should be avoided. Based on this analysis, we consider the 
PEG35k-DEX500k pair the most suitable for ATPS-mediated 
production of cancer cell spheroids. This analysis demonstrates 
the broad utility of different ATPS for 3D culture beyond PEG-
DEX ATPS primarily used in this study. 
 2.4.  Characterization of Consistency of Spheroids Size and 
Single Spheroid Formation in DEX Phase Drops 
 Evaluation of cellular response to therapeutic compounds in 
a 3D microenvironment requires integrating spheroid cul-
ture into robotic systems for high throughput compound 
screening. [ 4 ] Therefore we adapted the ATPS spheroid micro-
technology to a standard 96-well plate format to accommodate 
screening of several compounds or multiple concentrations of 
a compound within a plate. Using a commercial robotic liquid 
handler equipped with an air displacement pipetting head 
compatible with 96-well plates, a sub-microliter volume of the 
aqueous DEX phase containing cells is simultaneously dis-
pensed into all wells to form an individual cell-containing drop 
in each well. Incubation results in formation of a single sphe-
roid. The size of spheroids within a plate is inherently sensitive 
to variations in the volume of dispensed DEX drops. Thus, we 
examined distribution of size of DEX drops and resulting sphe-
roids by dispensing a 400 nL drop containing 1 × 10 4 cells in 
each well. To ensure complete dispensing of the viscous DEX 
Adv. Funct. Mater. 2014, 24, 6509–6515
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 Figure 2.  a) Side view of a DEX phase drop in the immersion PEG phase formed on a glass surface using equilibrated phases from an ATPS with 
initial composition of 6.4%(w/w) DEX and 5%(w/w) PEG. b) A top-view of A431.H9 skin cancer cell spheroid formed with a cell density of 1 × 10 4 cells 
at 24 h. c) Scanning electron microscope (SEM) image of A431.H9 cells after one week of incubation. d) Spheroids generated using a wide range of 
density of cells, i.e., 1 × 10 3 – 1 × 10 5 cells/spheroid, to demonstrate the feasibility of forming different sizes of tumor models.
 Figure 3.  Aqueous solutions of a library of different polymers were tested 
in pairs for the formation of an ATPS (upper right diagonal of the table) 
and spheroid (lower left diagonal of the table). Hatched cells indicate suc-
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phase, 600 nL of pre-aspirated air volume was dispensed fol-
lowing the aqueous DEX phase. This protocol resulted in DEX 
drops of 993 ± 101 µm and spheroids of 333 ± 28 µm in diam-
eter, respectively, within a plate at 24 h ( Figure  4 ). Incubating 
spheroids for an additional day led to an increased circularity, 
defi ned as the ratio of largest and smallest diameters, indi-
cating that spheroids become more compact (Figure  4 , inset). 
In addition, the average diameter of spheroids showed a slight 
increase to 349 ± 28 µm due to the growth of cells (Figure  4 , 
inset). Following this protocol, we were able to consistently 
form spheroids in multiple 96-well plates with a standard devia-
tion of ≈8% (Figure SI-2). 
 In addition to consistency of size of spheroids, gener-
ating a single spheroid in each well is crucial for compound 
screening applications. We found that with the ATPS approach, 
this is sensitive to the cell density within a drop. Therefore we 
established an experimental phase diagram to determine a 
minimum cell density for a given drop volume to give a single 
spheroid. Drops of the DEX phase with six different volumes 
in the range of 50–500 nL containing cell densities of 0.5 × 10 3 
– 10.0 × 10 3 per DEX drop were dispensed into wells and for-
mation of a single spheroid or multiple spheroids was evalu-
ated at 24 h. Each condition was set with 8 replicates. For each 
drop volume, we found a minimum cell number to guarantee 
formation of a single spheroid. This resulted in the phase dia-
gram of  Figure  5 . The hatched area to the right of each volume 
indicates cell densities that generate one spheroid within the 
drop whereas the area to the left of each volume gives multiple 
spheroids. Within the range of drop volumes and cell densities 
studied, data follow a linear correlation that can be used to pre-
determine a drop volume needed to generate a single spheroid 
of desired cell density (Figure SI-3). 
 2.5.  Spheroid Growth During Long-term Culture 
 Next we examined the compatibility of the assay with long-term 
culture. Spheroids of four different cell densities of 2.5 × 10 3 , 
3.5 × 10 3 , 5.0 × 10 3 , and 7.5 × 10 3 were generated within 200 nL 
DEX drops immersed in the PEG phase. Each condition was set 
Adv. Funct. Mater. 2014, 24, 6509–6515
www.afm-journal.de
www.MaterialsViews.com
 Figure 4.  Distribution of diameter of DEX drops (squares) and spheroids (circles) within a 96-well plate at 24 hrs of incubation. Dispensing of the DEX 
phase was carried out at a small fl ow rate and 0.2 mm above the well surface followed by dispensing of an air volume of 600 nl. Spheroids formed 
from a cell density of 1 × 10 4 cells within 400 nL-volume DEX drops. Average diameters of drops and spheroids are 993 ± 101 µm and 333 ± 28 µm, 
respectively. The inset graph represents the change in the average circularity of spheroids within the incubation period of 24 h to 48 h. Spheroids 
become more compact and their average diameter increase by 1.1% ( p < 0.05).
 Figure 5.  An experimental phase diagram determines the correlation 
between the volume of a DEX drop and the minimum number of cells 
in the drop to result in formation of a single spheroid. The area of single 
spheroid formation for drop volumes of 50–500 nL is highlighted by the 
hatched pattern. A linear equation of  V = (0.058) N + 47.6 fi ts the data ( V : 
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with 48 replicates, that is, half of a 96-well plate. After allowing 
24 hrs for formation of a single spheroid within each well, we 
added 50 µL of growth medium to wells to dilute out the con-
centration of polymers and produce a single medium phase. 
Therefore the ATPS was used as a patterning medium during 
the fi rst 24 h of culture only and thereafter, spheroids were 
maintained in a homogenous growth medium phase. Spheroids 
were imaged every other day, and 50 µL of medium of each well 
was robotically replenished to provide fresh nutrients to cells. 
The volume of each spheroid was calculated from its measured 
diameter assuming a spherical shape.  Figure  6 shows that the 
volume of spheroids of all four densities increases consistently 
over the one-week of culture, demonstrating that spheroids are 
viable, proliferative, and exhibit normal growth. As anticipated, 
larger density spheroids show greater growth indicated by the 
slope of growth curve (e.g., 0.025 mm 3 /day for spheroids of 
largest cell density and 0.006 mm 3 /day for the smallest den-
sity spheroids). The ease of generating and maintaining sphe-
roids in standard 96-well plates and robotic exchange of media 
enables convenient long-term culture for at least seven days to 
allow studying growth dynamics of spheroids. 
 2.6.  Cancer Cell Spheroids Response to Drug Compounds 
 To demonstrate the feasibility of high throughput compound 
screening with this 3D culture technology, we selected two 
epithelial cancer drugs and evaluated their effi cacy against 
spheroids of A431.H9 skin cancer cells. Cisplatin was used in 
a range of 20 n M –3 m M with 16 concentrations and paclitaxel 
was used in 1 n M –10 µ M range with 10 different concentrations. 
Parallel experiments were set with monolayer culture of cells at 
similar concentrations to examine differential response of cells 
to drugs compared to 3D cultures. Both spheroid and mon-
olayer cultures showed a dose-dependent response to the drugs. 
With cisplatin-treated monolayer culture ( Figure  7 a, circles), the 
drug showed effi cacy in a window of 6–130 µ M with LD50 value 
of 29.2 µ M and a lowest viability of ≈10% at the highest con-
centrations used. For spheroids treated with cisplatin (Figure 
 7 a, triangles), the effective range signifi cantly widened and 
increased to 20–600 µ M , resulting in LD50 of 131.7 µ M and a 
lowest viability of ≈30% at the highest concentration. Paclitaxel 
was a more potent compound and reduced the viability of mon-
olayer cultures within 1–100 n M , resulting in LD50 of 22.1 n M 
and a minimum viability of ≈35% at concentrations greater 
than 100 n M (Figure  7 b, circles). The use of spheroid cultures 
shifted the effective range of paclitaxel to 50 n M –1 µ M , increased 
the LD50 value to 178.5 n M , and reduced cellular viability to 
≈40% at concentrations larger than 1 µ M (Figure  7 b, triangles). 
Greater resistance of cells to drugs is most likely caused by the 
3D compact confi guration of spheroids that limits diffusion of 
drugs into the core of spheroids. [ 1,16 ] In addition, close intercel-
lular contact in spheroids can induce changes in gene expres-
sion to confer drug resistance in cells. [ 17 ] These tests highlight 
 Figure 6.  Spheroids formed using four different cell densities, each with half of a 96-well plate, and incubated for 7 days. Inset images show the growth 
of spheroids from a cell density of 5 × 10 3 over the 7-day culture. Data from spheroids of different densities at each day are statistically different ( p < 
0.05). Except for day 1–3 of the 2.5 × 10 3 density and day 3–5 of the 3.5 × 10 3 density, spheroid volume data for each cell density over the 7-day culture 
are statistically different ( p < 0.05). 
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the need for testing effi cacy of drugs with spheroid models 
because they closely mimic tumor physiology in vivo and elicit 
more realistic cellular responses. 
 To evaluate the robustness of this technology for drug 
screening with spheroids, we calculated the  Z ′ factor using the 
viability data from each drug corresponding to 50% viability 
as positive control and no drug treatment as negative control. 
The  Z ′ factor is a measure of robustness of high-throughput 
screening assays where values in the range of 0.5–1.0 indicate 
an excellent assay. [ 18 ] This test returned  Z ′ factor values of >0.6, 
with both cisplatin and paclitaxel demonstrating that the ATPS 
spheroid technology can robustly predict effects of drugs on 3D 
culture of cancer cells. 
 3.  Conclusions 
 3D cultures of cancer cells as spheroids present a physiologi-
cally relevant in vitro model that captures some key features 
of solid tumors and provides an essential tool for compound 
screening to identify potent anti-cancer drugs. Despite these 
recognized advantages, spheroids remain underutilized in high 
throughput screening applications due to limitations of existing 
techniques. We present a new approach for 3D culture of 
cancer cells using immiscible aqueous solutions of two biopoly-
mers. A drop of the denser aqueous phase containing cancer 
cells settles in the immersion aqueous phase to facilitate aggre-
gation of cells and formation of a compact spheroid without 
external forces. Immersion of spheroids in a bath of media 
throughout culture eliminates media evaporation and resulting 
alterations in drug concentrations inherent to hanging drop-
based approaches. [ 8,19,20 ] Adapting this approach to robotic 
liquid handling allows formation of consistent size spheroids 
in standard 96-well plates, each well containing a single sphe-
roid, to allow biochemical assays of cell responses in situ using 
plate readers. This is an essential feature for effi cient high 
throughput screening applications in drug discovery and devel-
opment. [ 6,20,21 ] Robotic media exchange and addition of drugs 
and reagents and biochemical analysis of spheroids viability 
using standard plate readers is convenient and straightforward. 
Spheroids show normal growth over a one-week culture and 
present signifi cant resistance to conventional anti-cancer drugs 
compared to monolayer cell cultures. This approach to 3D cul-
ture of cancer cells will benefi t a broad range of applications in 
tissue engineering and drug library screening without a need 
for special plates, devices, and facilities. 
 4.  Experimental Section 
 Phase Diagram Generation : Stock aqueous solutions of polyethylene 
glycol (PEG) and dextran (DEX), each 20%(w/w), were prepared 
in distilled water. Aqueous two-phase systems (ATPS) of different 
compositions were prepared using dilutions of the stock PEG and DEX 
solutions to yield systems in the range of 0.56%(w/w) PEG–19%(w/w) 
DEX to 16%(w/w) PEG–0.94%(w/w) DEX. Each ATPS was titrated drop-
wise with distilled water until a one-phase system formed. The added 
weight of diluent was used to calculate the fi nal composition of each 
ATPS and construct a binodal curve separating regions of two-phase 
formation from a single phase. 
 Aqueous Two-Phase System (ATPS) Formation with Different Polymers : 
We evaluated the formation of an aqueous two-phase system (ATPS) 
using pairs of the following polymers at a wide range of concentrations: 
polyethylene glycol, Mw: 35,000 (PEG35k, Sigma-Aldrich), polyethylene 
glycol, Mw: 8,000 (PEG8k, Sigma-Aldrich), dextran Mw: 500,000 
(DEX500k, Pharmacosmos), polyvinylpyrrolidone, Mw: 40,000 (PVP40k, 
Sigma-Aldrich), polyvinyl alcohol, Mw: 23,000 (PVA23k, Sigma-Aldrich), 
and polyacrylamide, Mw: 10,000 (PAAM10k, Sigma-Aldrich). All 
polymers were in powder form except for PAAM10k that was a 50 wt% 
aqueous solution. Polymers were dissolved in ultrapure water at a 
solubility recommended by the manufacturer and subsequently diluted 
to smaller concentrations. To facilitate dissolving of polymers, solutions 
were vortexed and then kept in a 37 °C water bath for 1 h. Stock polymer 
solutions were stored at 4 °C until use. Equal volumes of pairs of different 
concentrations from each two polymers were mixed in microcentrifuge 
tubes to a volume of 1 mL. Tubes were kept vertical in a rack at room 
temperature to allow polymer solutions equilibrate overnight. Formation 
of an ATPS was visually confi rmed if a thin interface separating a lighter 
top phase and a denser bottom phase was observed. 
 Cell Culture : A431.H9 skin cancer cells were kindly provided by Dr. 
Mitchel Ho (Center for Cancer Research, NIH, Bethesda, MD) and 
maintained in DMEM supplemented with 10% FBS, 1% glutamine, 
and 1% antibiotic. Every 10 passage, cells were treated with 700 µg/mL 
 Figure 7.  Drug screening with ATPS-generated spheroids compared 
to monolayer culture of cells. Percent viability of A431.H9 cells in 2D 
culture (circles) and 3D culture (triangles) treated with a) cisplatin and 
b) paclitaxel. After formation of spheroids at 24 h, cisplatin and paclitaxel 
were added at a concentration range of 20 n M –3 m M and 1 n M –10 µ M , 
respectively. Each concentration included two columns of a 96-well plate 
( n = 16). Control condition (no treatment) also had 16 replicates. Mon-
olayer cultures were treated with similar drug concentrations and number 
of replicates. Cellular viability was evaluated at 48 h using PrestoBlue. 
For each drug concentration, cell viability was calculated as the ratio of 
average fl uorescent intensities from drug-treated wells and control wells. 
Dashed lines are a sigmoid fi t to the experimental data. Error bars repre-
sent 95% confi dence limits.
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of G418 (Sigma-Aldrich). Cells were cultured at 37 °C and 5% CO 2 
and harvested using 3 mL of trypsin (Life Technologies), which was 
neutralized with 6 ml of growth medium. The cell suspension was 
centrifuged at 1000 rpm for 5 min, cells were resuspended in 1 ml of 
medium and counted with a hemocytometer. 
 Spheroid Culture : Aqueous solutions of 5%(w/w) PEG and 
12.8%(w/w) DEX were prepared in growth medium. A pre-defi ned 
number of A431.H9 cells suspended in growth medium was mixed 
thoroughly with an equal volume of 12.8% DEX and loaded into one 
column of 384-well plate, labeled as the source plate. Each well of a 
non-adherent, round-bottom 96-well plate, labeled as the destination 
plate, was loaded with 50 µL of 5%(w/w) PEG phase. Both plates were 
placed on the working surface of a robotic liquid handler (SRT Bravo, 
Agilent). The tip magazine of the liquid handler loaded 8 pipette tips 
(0.1–10 µL, Agilent) onto one column of the pipetting head, aspirated 
a defi ned volume of cell suspension in the DEX phase (e.g., 300 nL) 
into each tip, and dispensed it into each well of the destination plate 
0.1 mm away from the well surface. This was followed by dispensing 
600 nL of air to completely empty the tips and form a drop at the 
bottom of the well. The destination plate was incubated at 37 °C and 
5% CO 2 . Spheroids were imaged every other day and 50 µl of medium 
was refreshed. 
 Spheroid Formation with Different ATPS : From aqueous solutions of 
each two polymers (PEG35k, PEG8k, DEX500k, PVP40k, PVA23k, and 
PAAM10k) that formed an ATPS, we selected one pair with the lowest 
concentration of polymers for spheroid formation. Polymer solutions 
were prepared with growth medium. 50 µL of the lighter aqueous phase 
(immersion phase) was loaded into wells of a non-adherent 96-well plate 
(Nunc). The denser aqueous phase was thoroughly mixed with A431.H9 
cells at a density of 25 000 cells/µL and 0.2 µL of this suspension was 
dispensed into each well. After 48 h of incubation, wells were imaged 
with an inverted fl uorescent microscope (AxioObserver A1, Zeiss) to 
evaluate spheroid formation. 
 Drug Testing and Cellular Viability : Cisplatin (Spectrum Chemicals) 
and paclitaxel (Calbiochem) were dissolved in ultrapure sterile water 
at 2 mg/mL and dimethylsulfoxide (DMSO, ATCC) at 10 mg/mL, 
respectively. Working concentrations were prepared by serially diluting 
the stock solutions in growth medium. Spheroids and monolayer 
cultures were grown for 24 h and then treated with drugs for an 
additional 24 hrs. Drugs dilutions were prepared at twice the desired 
fi nal concentration before adding to an equal volume of culture medium 
in each well. Viability of cells in 2D and 3D cultures was evaluated using 
a PrestoBlue reagent (Life Technologies), which was added to wells at 
10% concentration of each well volume. Monolayer and spheroids 
cultures were incubated with PrestoBlue for 15 min and 6 h, respectively. 
Cell viability was determined using a standard microplate reader 
(SpectraMax M2, Molecular Devices) that measured the fl uorescent 
intensity from each well. All data were normalized against cell viability 
from control spheroids (no treatment). 
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